半水合雌二醇贴剂治疗绝经期症状的临床观察  

Clinical Observation of E_2 Transdermal Patch in the Treatment of Menopausal Syndrome

作　　者：郁琦[1] 郭欣[2] 张以文[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院,北京100730 [2]北京市东城区妇幼保健院,北京100007

出　　处：《实用妇产科杂志》2010年第2期107-110,共4页Journal of Practical Obstetrics and Gynecology

摘　　要：目的:评价半水合雌二醇贴剂(松奇)治疗绝经期症状的安全性、有效性和药物不良反应。方法:60例绝经期妇女,血清FSH>30U/L,E2<109.8pmol/L,随机分为实验组和对照组。实验组30例,连续使用半水合雌二醇贴剂,每7日更换1次,并每日口服甲羟孕酮2mg;对照组30例,每日口服戊酸雌二醇1.5mg,甲羟孕酮2mg;两组连续治疗12周。用药前及用药12周观察绝经症候群,测血清E2、FSH、脂蛋白、凝血功能,并观察安全性指标及药物不良反应。结果:两组绝经相关症状评分Kupperman指数有明显降低,绝经症候群有极显著改善,两组E2均值有明显升高。肝、肾功能,凝血功能及血糖无明显变化;实验组用药后脂蛋白a[Lp(a)]值明显下降,血脂谱其余各项均无明显变化。两组其他安全性指标差异无统计学意义。结论:半水合雌二醇贴剂治疗绝经期症状是安全、有效的,尤其适用于不适宜选择口服途径用药的妇女。Objective：To evaluate the security, efficacy and side effects of E2 transdermal patch （Fem-7） in the treatment of menopausal syndrome. Methods：A total of 60 cases with menopausal syndrome （ blood serum FSH 〉30 U/L,E2 〈 109.8 pmol/L） were randomly divided into treatment group （ Fem-7 group） and control group （estrodiol valerate（E2V） group） for 12 weeks treatment. Fem-7 group changed patch every 7 days and took the 2 mg medroxyprogesterone （MPA） every day. While the E2V group took the 2 mg MPA and 1.5 mg E2V every day. Serum E2, FSH, lipoprotein and coagulation function were evaluated at baseline and at the 12th week of the treatment. In addition, menopausal symptoms and some other index of security and side effects were also observed. Results：Kupperman indix in both groups was decreased and the mean value of E2 was increased obviously. Hepatic function, renal function, coagulation function and blood glucose were no obvious change. Lipoproteina was descended markedly in Fem-7 group. Other index of security in both groups was no obvious change. Conclusions： Fern-7 patch is secure and valid for relieving symptom of menopause, especially for the women who is not sutable for oral medication.

关 键 词：绝经症候群 雌激素 激素治疗 

分 类 号：R711.75[医药卫生—妇产科学]